Urs Wiedemann is a panelist on a workshop entitled “Let’s get personal: Advances in precision medicine are changing the way we identify and treat disease.”
CRA is a silver sponsor for this annual conference.
For more information on this event, click here.
Keytruda & PD-(L)1: Life after programmed death (Part 3)
As several market-leading PD-(L)1 inhibitors face imminent loss of exclusivity (LoE), the industry confronts a stark reality: technological innovation alone no...